

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number [000-21088](#)

OMB APPROVAL

OMB Number:	3235-0080
Expires:	March 31, 2018
Estimated average burden hours per response:	1.7

Issuer: [Fresh Tracks Therapeutics, Inc.](#)
Exchange: [Nasdaq Stock Market LLC](#)

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address: [9373 Towne Centre Drive, Suite 100](#)
[San Diego CALIFORNIA 92121](#)
Telephone number: [1 858 646-1100](#)

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

[Common stock](#)

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements for the Securities Exchange Act of 1934, [Nasdaq Stock Market LLC](#) certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

[2023-12-27](#) By

[Aravind Menon](#)

[Hearings Advisor](#)

Date

Name

Title

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. [See](#) General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Delisting Determination, The Nasdaq Stock Market, LLC, December 27, 2023, Fresh Tracks Therapeutics, Inc.

The Nasdaq Stock Market LLC (the Exchange) has determined to remove from listing the securities of Fresh Tracks Therapeutics, Inc., effective at the opening of the trading session on January 8, 2024.

Based on review of information provided by the Company, Nasdaq Staff determined that the Company no longer qualified for listing on the Exchange pursuant to Listing Rules 5101, 5110(b), 5550(a)(2), 5605(b)(1), 5605(c)(2), and 5605(d)(2). The Company was notified of the Staff determination on October 10, 2023. On October 17, 2023, the Company exercised its right to appeal the Staff determination to the Listing Qualifications Hearings Panel (Panel) pursuant to Rule 5815. A hearing on the matter was scheduled for December 21, 2023. On December 15, 2023, the Company withdrew its appeal. The Company securities were suspended on December 19, 2023. The Staff determination to delist the Company securities became final on December 19, 2023.